Viking Therapeutics (NASDAQ: VKTX) has captured the attention of investors, with its stock price skyrocketing over 400% in ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $61.68, with a -1.03% movement compared to the previous day. The stock's performance was behind the S&P 500's daily loss of 0.13%.

Viking Therapeutics VKTX has outperformed the market over the past 5 years by 41.66% on an annualized basis producing an ...

I'm bullish on Viking Therapeutics' weight-loss drug, but warn of risks and competition ahead. Click here to read my most ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

Recently revealed trial results for Roche's experimental weight-management drug suggest Viking Therapeutics is on the right ...

While it might not perfectly follow in the larger biotech's footsteps, TERN-601 has the potential to be one of the safer, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $70.47 which represents a slight increase of $2.31 or 3.39% from the prior close of $68.16. The stock opened at $69.5 and ...

Two stocks at opposite ends of the spectrum are Amgen (NASDAQ: AMGN), the healthcare behemoth, and Viking Therapeutics ...

Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive ...

That's the big thrill about owning Viking Therapeutics. If the company's GLP-1 treatment, referred to as just VK2735 for now, obtains approval, this already hot stock could become an even more ...